Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: Medtronic

This article was originally published in The Gray Sheet

Executive Summary

Medtronic: Rolls out four Thera-i pacemakers in the U.S. following PMA supplement approval by FDA on Nov. 6. The next-generation Thera devices offer about 30% longer service life and a more oval, "easier-to-implant" shape than the original Thera line, which remains on the market. Medtronic began marketing the Thera-i line in Europe in August. The devices sell at about a $200 premium to the earlier generation Thera pacemakers and range in price from $5,800 for the single chamber pulse generator and $6,500 for the single chamber rate responsive device to $7,000 for the dual chamber device and $7,500 for the dual chamber rate responsive device. The dual chamber models also have enhanced sensing and programming capabilities, the firm notes. Medtronic also announces release of its Model 5348 temporary pacemaker for critical care following marketing go-ahead from FDA...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT005026

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel